Does Blue Cross Blue Shield (Federated) Cover Farxiga (Dapagliflozin)?

What Farxiga Is and Why Insurance Tier Matters

Farxiga (dapagliflozin 10 mg once daily) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA across three distinct clinical populations. Its list price of approximately $620 per month makes tier placement on a pharmacy benefit plan the difference between a $45 copay and a $400 out-of-pocket bill. Understanding exactly where BCBS Federated slots this drug, and what conditions trigger prior authorization, lets prescribers write tighter PA justifications from the first submission.

Dapagliflozin received initial FDA approval on January 8, 2014 for glycemic control in adults with type 2 diabetes 1. The FDA subsequently expanded the label on May 5, 2020 to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with HFrEF 2, and again on April 30, 2021 to slow eGFR decline, reduce ESKD risk, and cut cardiovascular death in adults with CKD 3. Each new indication was supported by a separate large randomized trial, which insurance medical directors use to evaluate medical necessity. Citing the correct trial for the correct indication in a PA request is not optional.

The American Diabetes Association 2024 Standards of Care now list SGLT2 inhibitors as preferred agents for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, independent of HbA1c 4. That guideline language is directly quotable in a PA letter.

BCBS Federated Formulary Placement for Farxiga

Most Blue Cross Blue Shield Federated commercial plans place Farxiga on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays typically ranging from $75 to $150 per fill after deductible. Federal Employee Program (FEP) subscribers face slightly different formulary structures than commercial HMO or PPO members.

The Federal Employee Program, which covers approximately 5.5 million federal employees and dependents, maintains its own drug list called the FEP Blue Focus formulary 5. Farxiga appears on the FEP standard option formulary, but tier assignment varies by benefit year. The FEP 2024 pharmacy benefit placed dapagliflozin as a Tier 2 preferred brand under the standard option, with a 30-day retail copay of $60 and a 90-day mail-order copay of $120 5.

State-affiliated BCBS commercial plans (Anthem, Highmark, BCBS of Texas, BCBS of Michigan, and others operating under the BCBS license) maintain separate formularies. A patient in Texas may face Tier 3 placement while a patient in Michigan sees Tier 4. Always verify the specific plan's formulary at the BCBS member portal or by calling the pharmacy benefits number on the insurance card before submitting a PA request.

The ADA 2024 guidelines state: "For patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with proven cardiovascular benefit is recommended" 4. That sentence, cited verbatim with the ADA guideline URL, strengthens any PA submission.

Prior Authorization Criteria for Farxiga on BCBS Federated Plans

Prior authorization is required for Farxiga on the majority of BCBS Federated commercial and FEP plans. The specific clinical criteria differ by indication, and submitting documentation for the wrong indication is the most common reason for an initial denial.

For type 2 diabetes: Most BCBS plans require documentation of (1) an HbA1c at or above 7.0%, (2) a diagnosis code of E11.x, (3) a trial of metformin for at least 90 days unless a documented contraindication exists (renal impairment with eGFR <30 mL/min/1.73m2, lactic acidosis history, or intolerance), and (4) prescriber attestation that the patient has cardiovascular disease, HFrEF, or CKD if bypass of metformin step therapy is requested 6.

For heart failure with reduced ejection fraction: Coverage criteria typically require an LVEF of 40% or less confirmed by echocardiogram within the prior 12 months. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74 to 95% CI 0.65, 0.85, P<0.001) in patients with HFrEF regardless of diabetes status 7. Citing this specific hazard ratio in the PA narrative matters.

For chronic kidney disease: Plans typically ask for a documented eGFR between 25 and 75 mL/min/1.73m2 and a urine albumin-to-creatinine ratio (UACR) at or above 200 mg/g, consistent with the DAPA-CKD enrollment criteria 8. In DAPA-CKD (N=4,304), dapagliflozin reduced the primary composite outcome of sustained eGFR decline of 50% or more, ESKD, renal death, or cardiovascular death by 39% versus placebo (HR 0.61 to 95% CI 0.51, 0.72, P<0.001) 8.

PA approvals typically cover 12 months and require renewal with updated lab values. Turnaround time under federal mental health parity and ACA rules is 72 hours for urgent requests and 15 calendar days for standard non-urgent requests 9.

Step Therapy Requirements: What BCBS Federated Typically Demands

Step therapy, sometimes called "fail first," requires a patient to try and fail a less expensive drug before the plan will cover Farxiga. For type 2 diabetes, the required first-line agent is almost always metformin 500, 2 to 000 mg daily for a minimum of 90 days.

Failure of metformin is defined differently across plans. Some accept intolerance (GI adverse effects documented in chart notes). Others demand a lab-confirmed HbA1c still above 7.0% despite adherent use. Confirm the definition in the specific plan's formulary exception policy before the PA letter is drafted.

For HFrEF and CKD indications, step therapy through another SGLT2 inhibitor (empagliflozin, canagliflozin) is less common but possible on some Highmark and Anthem commercial plans. If the prescriber has a clinical reason to prefer dapagliflozin specifically (for example, the CKD label for dapagliflozin extends to eGFR as low as 25 mL/min/1.73m2 while empagliflozin's CKD label requires eGFR of at least 20 mL/min/1.73m2 10), that distinction belongs in the PA narrative.

The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure gives dapagliflozin a Class I, Level of Evidence A recommendation for patients with HFrEF to reduce hospitalization and cardiovascular mortality 11. Class I recommendations from major specialty societies are among the strongest arguments against requiring step therapy.

How to Appeal a BCBS Federated Denial of Farxiga

Denials happen. A clean, well-documented appeal reverses them more often than most patients and prescribers expect. The CMS data on ACA-compliant plans show that internal appeal overturn rates for prescription drug denials average around 40 to 60% when medical documentation is complete 12.

The appeal process for BCBS Federated plans follows four sequential levels:

1. Internal appeal (Level 1). Submit within 60 to 180 days of the denial notice (check the state-specific deadline on the denial letter). Include the PA letter, office visit notes documenting the diagnosis, lab results (HbA1c, eGFR, UACR, echo report as relevant), and the specific guideline citations listed above. Ask the prescriber to sign a "Peer-to-Peer" call request simultaneously, which in some BCBS affiliates bypasses the written appeal entirely.

2. Peer-to-peer review. A board-certified physician on the HealthRX medical team or the prescribing cardiologist/nephrologist/endocrinologist calls the BCBS medical director. Peer-to-peer calls for dapagliflozin in HFrEF are highly favorable given the Class I AHA/ACC recommendation 11.

3. External Independent Review Organization (IRO). If the internal appeal is denied, federal law under the ACA requires BCBS to offer an external review by an IRO within 72 hours for urgent cases and 45 days for standard cases 13. IRO reviewers are not BCBS employees and overturn rates at this level for drugs with Class I guideline support are significant.

4. State insurance commissioner complaint. Filing a complaint with the state's department of insurance creates a regulatory record. Several state affiliates have conceded denials after commissioner involvement rather than face a compliance review.

Throughout every level, keep dated copies of all correspondence. Federal law prohibits the plan from canceling coverage or retaliating while an appeal is pending 13.

Farxiga Cost Without Insurance and Savings Programs

Without insurance, Farxiga 10 mg (30 tablets) carries a manufacturer list price near $620 per month. Cash-pay prices at major pharmacy chains average $595, $640 depending on location.

AstraZeneca's Farxiga Savings Card reduces out-of-pocket cost to as low as $10 per 30-day fill for commercially insured patients who meet eligibility criteria, which excludes Medicare, Medicaid, and government-funded plans 14. The savings card applies even when Farxiga is on Tier 3 or Tier 4, provided the plan does not explicitly prohibit co-pay accumulator programs from applying manufacturer assistance to the deductible.

Patients enrolled in BCBS FEP plans should be aware that FEP runs a co-pay accumulator adjustment program, meaning manufacturer copay assistance may not count toward the annual deductible or out-of-pocket maximum. This is an important cost-planning consideration distinct from the monthly copay amount itself.

For patients who do not qualify for the savings card, AstraZeneca's AZ&Me prescription savings program offers free or reduced-cost Farxiga for patients below 600% of the federal poverty level without qualifying drug coverage 15. Income documentation is required.

The FDA's 2024 approval of a generic dapagliflozin is still pending at the time of this article's last review. No AB-rated generic is commercially available in the United States as of July 2025.

Clinical Evidence Underpinning Coverage Decisions

Insurance medical directors at BCBS Federated affiliates cite the same landmark trials that the FDA used to expand dapagliflozin's label. Knowing the trial design, the primary endpoint, and the magnitude of benefit lets prescribers speak the same language as the reviewer.

DAPA-HF (NEJM 2019, N=4,744): Patients with HFrEF (LVEF 40% or less) were randomized to dapagliflozin 10 mg daily or placebo on top of standard therapy. The primary composite endpoint of worsening heart failure or cardiovascular death occurred in 16.3% of the dapagliflozin group versus 21.2% of placebo (HR 0.74, P<0.001). The benefit was consistent regardless of whether patients had type 2 diabetes 7.

DAPA-CKD (NEJM 2020, N=4,304): Adults with CKD (eGFR 25 to 75 mL/min/1.73m2, UACR 200, 5 to 000 mg/g) on renin-angiotensin system blockade were randomized to dapagliflozin 10 mg or placebo. The primary composite of sustained eGFR decline of 50% or more, ESKD, or renal or cardiovascular death was reduced by 39% (HR 0.61, P<0.001). The trial was stopped early at a median follow-up of 2.4 years because of overwhelming efficacy 8.

DECLARE-TIMI 58 (NEJM 2019, N=17,160): The cardiovascular outcomes trial for dapagliflozin in type 2 diabetes showed a significant reduction in hospitalization for heart failure compared with placebo (HR 0.73 to 95% CI 0.61, 0.88) across a broad population with or without established atherosclerotic cardiovascular disease 16.

These three trials together justify PA approval across all three FDA-labeled indications. A PA letter that references each trial by name, sample size, and primary result is substantially harder to deny than one that says "clinical studies support use."

Does BCBS Federated Cover Farxiga for Weight Loss?

No. Weight loss is not an FDA-approved indication for dapagliflozin, and BCBS Federated plans do not cover it for that purpose. Farxiga produces a modest average weight reduction of 2 to 3 kg in clinical trials, largely through glycosuria, but the FDA has not granted a weight-management indication for this drug 17.

Prescribers who document weight loss as the primary reason for requesting Farxiga will receive an automatic denial. The submitted diagnosis code must match one of the three approved indications: type 2 diabetes (E11.x), heart failure (I50.x), or CKD (N18.x). Listing weight management as a secondary or collateral benefit does not trigger a denial but should not appear as the primary indication.

Patients seeking pharmacologic weight management through a BCBS Federated plan should discuss semaglutide (Wegovy) or tirzepatide (Zepbound), both of which carry FDA approvals specifically for chronic weight management and have their own distinct PA pathways.

Prescriber Documentation Checklist for a First-Pass BCBS Approval

The following framework reflects the documentation elements most commonly requested by BCBS Federated medical reviewers. Submitting all items simultaneously with the initial PA request reduces denial rates and eliminates the most common reason for delay: incomplete clinical records.

For type 2 diabetes indication:

• Current HbA1c result with date (must be within 90 days for most plans)
• eGFR result with date (confirms renal dosing eligibility)
• Documentation of metformin trial (start date, dose, duration, reason for discontinuation or continued use)
• ICD-10 code E11.x as primary diagnosis
• Co-morbidity codes for ASCVD, HFrEF, or CKD if bypass of step therapy is sought
• ADA 2024 guideline citation 4

For HFrEF indication:

• Echocardiogram report showing LVEF 40% or less (within 12 months)
• ICD-10 code I50.2x or I50.4x
• Current GDMT regimen (ACEi/ARB/ARNI, beta-blocker, MRA)
• DAPA-HF trial citation 7
• AHA/ACC/HFSA 2022 Class I recommendation citation 11

For CKD indication:

• eGFR 25 to 75 mL/min/1.73m2 (dated within 90 days)
• UACR 200 mg/g or higher (dated within 90 days)
• Documentation of ACE inhibitor or ARB use
• ICD-10 code N18.3 or N18.4
• DAPA-CKD trial citation 8

Submitting a peer-reviewed, indication-specific clinical summary sheet alongside these items has reduced first-pass PA denial rates in the HealthRX patient population. Most BCBS PA reviewers make decisions within 3, 5 business days of receiving a complete submission.

Monitoring Requirements That May Affect Ongoing Coverage Renewal

PA renewals at 12 months typically require updated labs. BCBS Federated reviewers will want evidence that the drug is producing measurable clinical benefit.

For type 2 diabetes renewals, updated HbA1c (goal typically below 8.0% or a reduction of at least 0.5 percentage points) and stable or improved eGFR are standard requirements. For HFrEF renewals, a repeat echo is not always mandated, but an updated clinical note confirming symptom stability or improvement supports the renewal. For CKD renewals, a current eGFR and UACR showing the drug is slowing progression (or that the patient has not yet progressed to ESKD) satisfies most reviewer checklists 18.

Dapagliflozin is generally continued even when eGFR drops below 25 mL/min/1.73m2 in the CKD population, because the renal protective effect persists at lower function levels in post-hoc analyses of DAPA-CKD 8. Document this explicitly in the renewal letter if the patient's eGFR has declined since the original approval.